FDA Approves Opsynvi (macitentan and tadalafil) for Adults with Pulmonary Arterial Hypertension

RARITAN, NJ, March 22, 2024– Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Opsynvi®– a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news